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Over the last decades, the increasing knowledge in the area of rheumatoid arthritis has progressively expanded the arsenal of
available drugs, especially with the introduction of novel targeted therapies such as biological disease modifying antirheumatic
drugs (DMARDs). In this situation, rheumatologists are offered a wide range of treatment options, but on the other side the need
for comparisons between available drugs becomes more and more crucial in order to better define the strategies for the choice and
the optimal sequencing. Indirect comparisons or meta-analyses of data coming from different randomised controlled trials (RCTs)
are not immune to conceptual and technical challenges and often provide inconsistent results. In this review we examine some
of the possible evolutions of traditional RCTs, such as the inclusion of active comparators, aimed at individualising treatments in
real-life conditions. Although head-to-head RCTsmay be considered the best tool to directly compare the efficacy and safety of two
different DMARDs, surprisingly only 20 studies with such design have been published in the last 25 years. Given the recent advent
of the first RCTs truly comparing biological DMARDs, we also review the state of the art of head-to-head trials in RA.
1. Introduction
Based on the wrong assumption of a possible interference
with proliferation of connective tissues, methotrexate (MTX)
was first trialled for the treatment of rheumatoid arthritis
(RA) in 1962 [1]. Definite approval of MTX as a therapy for
active RA came in 1988 after two placebo-controlled studies
involving a total of 224 patients treated for a maximum of 24
weeks [2, 3]. Much has changed since then in drug discovery
and trial design in RA. The identification of tumor necrosis
factor (TNF) as a key player in the inflammatory and destruc-
tive pathways of the disease initiated a landmark shift of inter-
est away from agents with poorly understood mechanisms of
action towards therapies targeted to key molecules and cells
involved in RA pathogenesis [4]. Advances in understanding
of the role of T cells, B cells, and cytokines such as IL-6 have
paved the way to the development of additional biological
drugs beyond TNF-inhibitors, such as abatacept (ABT),
rituximab, and tocilizumab (TCZ) [5–10]. These have come
to formal approval after randomised controlled trials (RCTs)
mostly adherent to the recommendations from the US Food
and Drug Administration (FDA) and the European Agency
for the Evaluation of Medicinal Products (EMA). Specific
requirements include long-term RCTs (12 to 24 months in
duration) evaluating radiographic progression, and patient-
reported physical function in addition to accepted outcomes
assessing signs and symptoms [11, 12]. Table 1 summarises
RCTs of biological disease-modifying antirheumatic drugs
(DMARDs) that have supported regulatory labelling [13–45].
After more than ten years of experience, biological DMARDs
have consistently shown good efficacy and safety in patients
with RA [46–51].
The ever-increasing plethora of effective treatment
options for patients with RA undoubtedly reflects the vitality
of research in this area. The paradox, however, is that
rheumatologists have little or no idea of how to approach
an individual patient to best utilise this vast arsenal. As a
proof, updated recommendations for the management of
RA still refer to homogeneous disease populations (with the
exception of few and ill-defined prognostic factors) and,
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most importantly, do not assist in the choice and optimal
sequencing of available biological DMARDs [52–54]. This
area of uncertainty is likely to increase with the upcoming
introduction of biosimilar and targeted synthetic DMARDs
on the market.
Classic RCTs sponsored by pharma industries to assess
the efficacy and safety of new compounds clearly do not
fit well with the urgent need of improving decisions that
affect medical care at the levels of both policy and the
individual. Most of the RCTs in RA indeed exclude com-
monly used comparator interventions and clinically relevant
patient subgroups. These exclusions diminish the ability to
understand the relative merits of different interventions and
the generalisability of the trial results [55]. Although compar-
ative efficacy and effectiveness can be informed by analysis
of observational data, decision modelling, and other tools
(reviewed in [56, 57]), theRCT still remains themost rigorous
method for comparing interventions. However, trial designs
should be substantially rethought in order to allow reliable
assumptions on the effectiveness of different interventions
among patients in typical day-to-day practice. In this review,
we will first briefly summarise how and to what extent the
dearth of evidence from comparative RCTs in RA can be
partially counterweighted by indirect comparisons. We will
then examine some of the possible implementations to classic
RCTs, such as the inclusion of active comparators and new
trial designs, to align research methods to current demands.
In light of the recent advent of the first RCTs truly comparing
biological DMARDs, we will also review the state of the art of
head-to-head trials in RA.
2. Indirect Comparisons and Meta-Analysis
In contrast to direct within-trial comparison, in indirect
comparisons, the effects of interventions are compared to
each other by their performance against a common compara-
tor. Quantitative results of several similar studies comparing
the same intervention with the same comparator can be
combined by means of meta-analysis to summarise the
available evidence into a pooled estimate of the outcome
of interest (pairwise meta-analysis). Furthermore, multiple
different pairwise comparisons across a range of different
interventions can be combined into network meta-analysis
(also known as mixed treatment comparisons or multiple
treatment meta-analyses) [58, 59].
Of key importance in indirect comparisons is not to break
randomisation, thus preserving the advantages of RCTs. If
one trial compares drug A versus placebo and a second trial
compares drug B versus placebo, it is incorrect to simply
compare the absolute efficacy observed with drug A with that
observed with drug B. Indeed, part of the absolute efficacy
can be attributed to the drug, whereas another part is due to a
placebo effect. Furthermore, differences in absolute treatment
effects may be a result of different baseline prognostic factors.
In order not to break randomisation, one can only compare
the relative effect of drug A versus placebo from one trial
with the relative effect from other trials (adjusted indirect
comparison) [60].
Basic assumptions underlying indirect comparisons
include that results from different trials should be sufficiently
homogeneous [61] by either fixed-effects models or random-
effects models. In fixed-effects models, it is assumed
that differences in true relative treatment effects are only
caused by the difference in treatment and no other factors.
In random-effects models, differences in study-specific
treatment effects (beyond the differences attributable to the
interventions compared) are exchangeable, and heterogeneity
is constant between the different comparisons [62]. Another
assumption for an adjusted indirect comparison to be valid
is similarity [61]. This means that patients included should
be sufficiently similar in the two sets of placebo-controlled
trials, so that the relative effect estimated by trials of A versus
C is generalisable to patients in trials of B versus C, and the
relative effect estimated by trials of B versus C is generalisable
to patients in trials of A versus C. Last, when both direct and
indirect evidence is available, an assumption of consistency
is required to quantitatively combine the direct and indirect
estimates [61]. Possible causes of discrepancy (inconsistency)
between the direct and indirect evidence include the play of
chance, invalid indirect comparison, bias in head-to-head
comparative trials, and clinically meaningful heterogeneity
across trials.
Conclusions from meta-analysis are drawn by applying a
statistical inference technique,which can be either frequentist
or Bayesian [63].With a frequentist approach, the result of the
meta-analysis is a point estimate along with a 95% confidence
interval. Bayesian methods involve a formal combination of
a priori probability distribution (that reflects a priori belief
of the possible values of the pooled effect) with a likelihood
distribution of the pooled effect based on the observed data
to obtain a posterior probability distribution of the pooled
effect. The likelihood informs us about the extent to which
different values for the parameter of interest is supported
by the data. As such, the posterior distribution obtained
with the Bayesian approach can be interpreted in terms of
probabilities, which allows for a more intuitive interpretation
of the results.
Although being increasingly adopted to compare the
effects of different treatments in manymedical areas, indirect
comparisons are not immune to conceptual and technical
challenges. As treatments being compared have not been
randomised directly within the individual trials, standard
meta-analysis provides evidence of an observational nature
and thus suffers from the limitations of observational stud-
ies [61]. Furthermore, sometimes inconsistency cannot be
explained after considering effect modifiers. A recent meta-
epidemiological study indeed identified 14% of inconsistency
between direct and indirect comparisons [64].
Surprisingly, evidence for conventional DMARDs (MTX,
leflunomide [LEF], and sulfasalazine [SSZ]) in RA coming
from network meta-analysis combining direct and indi-
rect comparisons does not support the superiority of one
DMARD over another [65]. Limitations may stem from
the wide differences in MTX dosing across different trials.
The preferred use of MTX in most patients versus other
oral DMARDs is thus rather supported by extensive clinical
experience over the years [66]. For biological DMARDs, as
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head-to-head comparisons are only exceptions, thus, network
meta-analysis is the sole informative tool for comparative
effectiveness. Disappointingly, many of the published com-
parisons lead to different conclusions. As an example, a
2009 Cochrane overview failed to recognise significant dif-
ferences in efficacy among the available biological DMARDs
(with the exception of anakinra), whilst the safety profile
favoured etanercept (ETN) [67]. In contrast, Schmitz and
colleagues [68] reported superiority of ETN compared with
infliximab (IFL) and golimumab and of certolizumab com-
pared to infliximab and adalimumab (ADA). A number of
factors may account for such inconsistency, including the
RCTs being considered, the analysis of potential sources
of heterogeneity, and the efficacy outcomes assessed [69].
Additionally, some confounders, such as period of enrolment
of different RCTs, cannot be adequately corrected, limiting
the possibility of indirect comparisons for specific outcomes
(e.g., radiographic progression) [70]. These shortcomings
currently hamper the use of available indirect comparisons
as part of formal decision making strategies in RA.
3. Randomised Controlled Trials: New Designs
to Improve Comparative Effectiveness
The classic RCT that most rheumatologists are familiar with
is the two-armed, parallel-group efficacy trial comparing the
experimental treatment with placebo. This type of RCT is
clearly not aligned with the need of determining the optimal
strategy for individual patients in a community-based setting.
The use of active comparators instead of placebo will be dis-
cussed in a further section. Here, we will summarise possible
trial implementations aimed at individualising treatments in
real-life conditions.
3.1. Implementation by Study Design
3.1.1. N-of-1 Trials. The development of n-of-1 or single
subject clinical trials is based on the recognition of the
tremendous heterogeneity of diseased populations and the
need of individualised treatments. In a n-of-1 trial, the indi-
vidual patient is considered as the sole unit of observation,
with the ultimate goal of determining the optimal or best
intervention for that specific patient using objective data-
driven criteria [71]. Although n-of-1 trials, by definition,
eschew consideration of the population-level effects of an
intervention, combining and evaluating multiple n-of-1 trials
throughmeta-analysis can allow generalisability of the results
[72]. The typical design of a n-of-1 trial is a within patient
randomised, double-blind, and crossover trial. The unit of
randomisation is the treatment sequence for an individual
patient, and a treatment cycle includes an exposure to each
therapy. In contrast to classic randomised crossover trials,
where the individual is randomised to one group or another,
in n-of-1 trials each participant receives each intervention at
different time frames of the study.
N-of-1 trials have not been frequently adopted in rheuma-
tology, with the exception of studies of pain medications
in osteoarthritis. A study by Yelland et al. [73] provides a
good example. A comparison of celecoxib and paracetamol
was assessed. The design of the trial was based on a double-
blind, crossover comparison where a subject took either
celecoxib or sustained-release paracetamol for three pairs
of 2-week periods. The order of the drugs during each
pairing was random. Both patients and physicians did not
know the order of the drug regimens until after the study
was completed. Statistical analyses were conducted using
Bayesian methods. The aggregate results showed that most
(80%) patients completing the trial had a similar response to
celecoxib as to paracetamol.
3.1.2. Cluster Randomised Trials. In cluster RCTs, randomi-
sation is by group (such as communities, families, or medical
practices) rather by individual patient. Advantages of cluster
RCTs over individually randomised controlled trials include
the ability to study interventions that cannot be directed
toward selected individuals and the ability to control for
“contamination” across individuals, that is, the unintentional
spillover of intervention effects from one treatment group to
another. However, because of the dependence (or clustering)
between individual units sample, cluster RCTs require more
participants to obtain the same statistical power and aremore
complex to design, execute, and analyse [74].
Cluster RCTs are becoming increasingly common in
health services research, being particularly appropriate for
evaluating interventions aimed at changing behaviour in
patients or practitioners or changing organisation of ser-
vices. In RA, the effectiveness of systematic monitoring
of disease activity in daily practice was confirmed in a
multicentre cluster RCTs published in 2005 [75]. Twenty-four
rheumatology outpatient centres were randomly allocated
to systematic monitoring (0–4–12–24 weeks) using 28 joints
disease activity score (DAS28) versus usual care. At 24 weeks,
low disease activity (DAS28 ≤ 3.2) was achieved by 31% of the
patients in the DAS28 group compared to 16% of the patients
receiving usual care (𝑃 = 0.028) due to prompt changes in
DMARD treatment.
3.2. Implementation by Outcome of Interest
3.2.1. Pragmatic Trials. In efficacy (or explanatory) RCTs,
extended inclusion and exclusion criteria are used to identify
a clearly defined population of participants who would
benefit from the intervention under investigation. Although
efficacy trials, if correctly designed and executed, lead to
statistically credible results, the applicability of these results
to real-life practice may be questionable. Indeed, the same
characteristics that account for the high internal validity
(well-defined inclusion and exclusion criteria, blinding, and
controlled environment) can hamper external validity, that is,
the ability to generalise the results in an extended population
and clinical setting. Pragmatic RCTs, on the other hand, are
designed to test interventions in the full spectrumof everyday
clinical practice in order to maximise applicability and
generalisability [76]. Common elements of such trials include
clinically effective comparators, study patients with common
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comorbid conditions and diverse demographic characteris-
tics, and providers from community settings. Primary and
secondary outcomes are patient-centered. The distinction
between an explanatory and a pragmatic trial in real life is not
that easy. The Pragmatic-Explanatory Continuum Indicator
Summary (PRECIS) provides a useful framework to help
researchers design pragmatic trials [77]. This tool identifies
important domains (such as eligibility criteria, flexibility of
the intervention, patient adherence, practitioner expertise,
follow-up intensity, and outcomes) that should be considered
during protocol development of pragmatic RCTs. Pragmatic
trials arguably combine the advantages of randomisation
(high internal validity) and observational research (high
external validity). However, they also have important short-
comings. The increased variance due to the inclusion of
chronic/poorly responsive/comorbid patients, insensitive or
problematic outcome parameters, and inadequate sample size
increases the risk of a 𝛽-error (failure to detect a difference
although there is one), and unblinded designs can induce
different kinds of biases.
In RA, the most cited example of a pragmatic trial is the
Dutch Behandel Strategieen (BeSt) study [78]. Patients with
early, untreated, and activeRAwere randomly allocated to 1 of
4 treatment groups. Treatment strategies included sequential
monotherapy (group 1), step-up combination therapy (group
2), initial combination therapy with tapered high-dose pred-
nisone (group 3), or initial combination therapy with IFL
(group 4). Treatment adjustments were made on the basis
of the treat-to-target and tight control principles. Primary
endpoints were functional ability and radiographic joint
damage. Despite several limitations, such as unblinding and
intention-to-treat analysis, the BeSt study has contributed to
significant advances in the management of RA by demon-
strating that, in the majority of patients, a goal-steered,
dynamic treatment towards tight control of disease activity
ensures good clinical and radiographic outcomes irrespective
of the type, combination, and sequencing of therapies [79].
3.2.2. Adaptive Trials. A conventional study is planned using
assumptions about critical elements of the study design, such
as population means or event rates, variance, dose-response
effect size, discontinuation rates, that are not precisely known
but are only estimated. When the prestudy estimates are
inaccurate, a conventional study may fail to achieve its goal.
Data accumulating during the course of the study, however,
could provide improved knowledge of relevant parameters if
those data could be examined. Adaptive RCTs are designed
to change or adapt in response to information generated
during the trial [80, 81]. This could make the studies more
efficient (e.g., shorter duration, fewer patients), more likely
to demonstrate an effect of the drug if one exists, or more
informative. Importantly, adaptations (or changes) should
not be ad hoc, but by design, based on prospectively planned,
prespecified analyses of interim data. Points of weakness
of adaptive designs include feasibility, validity, integrity,
efficiency, and flexibility [81, 82].
Of the various adaptive design trials [81], biomarker-
driven adaptive studies perhaps offer the most attractive
prospects. Predictive biomarkers can be selected from a
wide array of prognostic biomarkers (which are useful for
projecting the natural history of a disease independent of
therapy) to define a specific subgroup of patients for which
treatment will be beneficial. An example of a predictive
marker is the presence or absence of K-Ras mutations in
colorectal cancers; patients without K-Ras mutations benefit
from antiepidermal growth factor receptor therapy, whilst
patients with such mutations derive little, if any, benefit
[83]. Where a single biomarker has been identified, several
trial designs can be employed [84], including (i) biomarker-
enrichment design, which involves only patients testing pos-
itive for the biomarker.This design is more appropriate when
there is preliminary evidence that patients testing positive
for the biomarker will likely benefit from the treatment;
(ii) biomarker-stratified design involves first testing patients
for the biomarker and then separately randomising patients
who test positive and those who test negative. This design is
more appropriate when there is no preliminary evidence to
strongly favour a positive or negative biomarker.Themedical
literature in oncology provides good examples of biomarker-
driven studies [85]. No similar trial strategies have been
adopted in RA yet. Paradoxically, despite anticitrullinated
protein antibodies (ACPA) are acknowledged as one of the
strongest prognostic factors of worst disease outcomes [86],
no clinical studies have tailored RA treatment based on a pos-
itive ACPA-test. However, evidence from the PROMPT study
seems to suggest that early MTX treatment in patients with
undifferentiated arthritis could significantly delay progres-
sion to RA specifically in ACPA-positive patients [87], con-
firming the possibility of identifying subgroups of patients
with treatment benefit at least in the earliest phases of the
disease [88]. The field of biomarker discovery is moving fast
in RA, fuelled by the implementation of systems biology and
omic technologies. The increased awareness of the systemic
and multidistrict nature of the disease have expanded the
possibility to search for novel biomarkers in different diseased
compartments [89–93]. Promising prognostic biomarkers (to
be further tested for their predictive ability) are emerging
in the peripheral circulation [94–97], and the accessibility
of the synovial tissue through minimally invasive techniques
[98] allows more extensive studies aimed at investigating the
clinical and prognostic significance of different pathological
features [99, 100].
4. Head-to-Head Trials
Undoubtedly, the use of a placebo control in RCTs offers
several advantages. Inclusion of placebo increases the effi-
ciency of a trial, as statistical significance can be achieved
with the smallest number of participants. Secondly, the results
of a placebo-controlled trial are usually unequivocal, with
clear evidence of whether the experimental drug being tested
is efficacious or not. There are few ethical concerns in
using placebo-controlled trials when no therapy of proven
effectiveness exists. In contrast, when standard therapy does
exist, controlling for placebo raises not only ethical but
also practical issues, in that the usefulness of the results is
ambiguous.
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Despite the fact the regulatory agencies recommend that
placebo should not be continued for more that 3–6 months
in RA trials [101], Estellat and Ravaud [102], through a
revision of all RCTs of biological DMARDs ended after 2002,
highlighted that 6,518 RA patients enrolled in control arms
were continuing their previously ineffective treatment for
more than 6 months. As such, a significant revision in the
requirements for the investigation and approval of new drugs
for the treatment of RA is needed. An International Commit-
tee has recently proposed that placebo can be acceptable for
no more than 3 months and new biological DMARDs should
be tested against an active comparator [103]. In light of their
tightest confidence intervals for efficacy, TNF-inhibitors (+
MTX) should be the comparator of choice [103].
Active control or comparative or head-to-head trials refer
to all studies in which the control arm is an active one. Based
on the scientific hypothesis behind the trial, comparative
trials may be classified as superiority, equivalence, or nonin-
feriority trials [104, 105].
In a superiority trial, the aim is to show that a new
treatment is better than standard therapy.The null hypothesis
is that the difference between the means of the two groups
is zero or negative (i.e., favouring the standard treatment)
versus the one-tailed alternative hypothesis that the new drug
is better. The desirable difference in treatment effects should
be decided on clinical grounds, considering the specific
features of the disease, the known efficacy of the control
therapy, and what may reasonably be expected from the new
therapy. The rationale for a one-sided test of significance
is that investigators are not interested in results that show
that the new drug is equal to or inferior than the standard.
However, a shortcoming of one-tailed tests is that significant
results in the opposite direction must be dismissed as chance
findings, despite having the potential of being clinically
meaningful. Superiority trials are almost never seen in active-
control trials because of the high risks of failure intrinsic
in their design and the required sample size, which can be
unachievable in certain conditions. Indeed, the smallest the
difference between the standard and the experimental drug
is expected, the largest will be the population required.
Equivalence trials test whether the effects of two drugs are
the same within prespecified limits. As it is fundamentally
impossible to prove that two treatments have exactly equiv-
alent effects, “clinical equivalence intervals” must be deter-
mined. The null hypothesis is that the difference between
treatments falls outside the interval versus the alternative
hypothesis that the differences lie within the equivalence
interval. Equivalence trials are based on two-sided tests,
which increase the sample size and the cost of the study.
Furthermore, equivalence margins are often far too large
to be clinically meaningful and a claim of equivalence may
be misleading if a trial has not been conducted to an
appropriately high standard. Equivalence trials are often run
when biosimilars are entering the market.
Noninferiority trials test whether the effect of a new
treatment is not worse than that of an active control by
more than a prespecified margin. Again, an interval of
noninferiority must be determined. The null hypothesis is
that the new drug is worse than the standard one by at
least some amount, against the alternative hypothesis that
the superiority of the standard drug does not exceed this
interval. However, since noninferiority trials do not include a
true negative control group, results of these trials are viewed
with caution and are not generally accepted as being as strong
as those from a superiority trial. Noninferiority trials are
carried out when (1) a placebo-controlled trial is not ethically
feasible and (2) the treatment under test is not expected to
be better that the standard or reference intervention in terms
of efficacy but is supposedly better regarding other secondary
endpoints, safety, costs, compliance, or convenience.
5. Head-to-Head Randomised
Controlled Trials in Rheumatoid Arthritis:
State of the Art
5.1. Synthetic DMARD versus Synthetic DMARD. The com-
parison between two different synthetic DMARDmonother-
apies for RAwas reported in 14 RCTs, all havingMTX as basis
for comparison (Table 2).
5.1.1. Auranofin (AUR). In a 36-week RCT randomising 281
patients with active RA toMTX or AUR, the clinical response
(swollen joint count [SJC] and tender joint count [TJC]) with
MTXoccurred earlier andwas consistently greater (𝑃 < 0.01)
than the one with AUR. Adverse reactions were reported
more frequently in the AUR group [106]. However, in a
subsequent RCT involving 335 patients and comparingMTX,
AUR, and the combination of both, no statistically significant
differences were found among the treatment groups in terms
of clinical response and safety profiles, even if patients taking
AUR alone had a slower onset of response than those taking
MTX alone [107].
5.1.2. Azathioprine (AZA). AZA was directly compared with
MTX in two RCTs with similar results. In the first one,
64 patients were randomly assigned to receive either AZA
(100mg daily) or oral MTX (7.5mg weekly): both clinical
responses (SJC, erythrocyte sedimentation rate [ESR], C-
reactive protein level [CRP], and DAS) at 24 and 48 weeks
checkpoints [108] and radiographic progression [109] were
significantly better in MTX treated group, accompanied by
a lower rate of serious adverse reactions. In the second study
[110], 209 enrolled patients were randomised to receive esca-
lating doses of MTX (5–15mg/week), AZA (50–150mg/day),
or the combination of both. The proportion of responders
was significantly higher in MTX treated group compared
with AZA (45% versus 26%, resp.) and a trend toward
decreased radiologic progression was seen only in MTX-
treated patients.
5.1.3. Cyclosporine A (CSA). Two RCTs compared CSA with
MTXwith different findings. Drosos et al. [111] demonstrated
a similar clinical response (SJC, TJC, ESR, and CRP) and
radiographic progression in two groups of early RA patients
(disease duration< 3 years) randomly assigned to receive oral
CSA (3mg/kg/day) or oral MTX (0.15mg/kg/week). More
recently, in an open RCT randomising 126 patients to MTX,
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CSA, or SSZ, American College of Rheumatology (ACR) 50
responses were significantly higher in MTX treated patients
compared with CSA (57% versus 31%, resp.; 𝑃 = 0.002) [112].
In both the studies, the proportion of adverse events (AEs)
was similar in MTX and CSA treated groups.
5.1.4. Intramuscular Gold (Gold Sodium Thiomalate [GST]).
GST showed a similar clinical response (ESR, CRP, Ritchie
Articular Index, and pain score) and a significantly higher
proportion of withdrawals for toxicity (43% GST versus
19% MTX, 𝑃 = 0.0026) compared to MTX in a 48-week
head-to-head RCT [113]. It should be noticed that in this
study MTX was used at relatively lower doses (median dose:
10mg/weekly) than the currently recommended optimal
doses. In a second double-blind RCT evaluating damage
progression, 174 patients were assigned to receive weekly
intramuscular injections of either 15mg MTX or 50mg
GST for 3 years. No statistically significant differences in
clinical efficacy and radiographic progression between the 2
treatment groups at all follow-up points were found [114].
5.1.5. Leflunomide (LEF). As part of the clinical development
program for LEF provided by the Leflunomide Rheumatoid
Arthritis Investigators Groups, patients were enrolled in 2
RCTs comparing LEF with SSZ and MTX, respectively. Since
the first one [115] was not powered to show equivalence
between the active treatments but only to indirectly compare
LEF and SSZ, the study has not been included in the current
review. In the second one, 482 patients were randomly
assigned to receive LEF (100mg daily on days 1–3, then 20mg
daily), placebo, or MTX (7.5mg weekly, titrated to 15mg
weekly over 7 weeks ). No statistically significant differences
were found in the comparison of LEF and MTX treated
patients regarding ACR20 response at 1- (52% versus 46%,
resp.) [116] and 2-years follow-up (79% versus 67%, resp.)
[117]. Moreover, radiographic progression at 1- and 2-year
evaluations [116, 117] and improvements in physical function
and health related quality of life at 2 years [118] were similar
in the 2 treatment groups.
A direct comparison between LEF and MTX was per-
formed in another RCT including 999 RA subjects ran-
domised to LEF (loading dose 100mg/day for 3 days, main-
tenance dose 20mg/day) or MTX (10–15mg/week) for 52
weeks [119]. After 1 year, improvements seen with MTX were
significantly greater than those with LEF in terms of ACR20
response (64.8 versus 50.5%; 𝑃 < 0.0001) and mean change
from baseline of TJC (−9.7 versus −8.3; 𝑃 = 0.006), SJC
(−9.0 versus −6.8; 𝑃 = 0.0001), physician global assessment
(−1.2 versus −0.9; 𝑃 < 0.001). Radiographic progression was
similar with both treatment protocols at 1 year, whereas a
significant difference inmean change from baseline of Larsen
score in favour of MTX was found at 2 years. The proportion
of AEs leading to withdrawal at 2 years (MTX 21%, LEF 27%)
and the overall frequency of serious AEs (MTX 8%, LEF 7%)
were comparable.
Besides, in a third comparative trial including 504 RA
patients evaluated during a 24-week follow-up period, LFN
was found as effective but safer thanMTX [120]. In particular,
62% patients in the LFN group met the ACR20 criteria
versus 60% in the MTX one, but the incidences of AEs were
significantly lower in LFN than in MTX treated patients
(16.8% versus 28.1%; 𝑃 = 0.002).
5.1.6. Sulfasalazine (SSZ). A direct comparison of SSZ with
MTX was performed in 3 RCTs [121–123], each designed
by the randomisation of study population (105, 205, and
165 patients, resp.) into 3 treatment arms (SSZ alone [2000
to maximum 3000mg daily], MTX alone [7.5 to maximum
25mg weekly], and the combination of two). In all these
studies, no significant differences emerged in the 1-year head-
to-head comparison between SSZ and MTX in terms of
clinical efficacy (measured asDAS), radiographic progression
(total sharp score), and frequency of AEs.
On the contrary, in the previously mentioned study by
Ferraccioli et al. [112] directly comparing MTX, CSA, and
SSZ, the proportion of patients achieving ACR50 response
at 12 months was significantly higher in MTX than in SSZ
treated group (57% versus 33%, 𝑃 < 0.01), with a similar
safety profile.
5.2. Synthetic DMARD versus Biological DMARD. The vast
majority of biotherapy related RCTs are designed to compare
MTX monotherapy with the combination of MTX and a
biological drug.Thus, only 4RCTs provided data on the direct
comparison between a synthetic and a biologic DMARD
monotherapy: the ERA study and the TEMPO trial evaluated
ETN, the PREMIER study ADA, and the AMBITION trial
TCZ, all head-to-head compared against MTX (Table 2).
The ERA study is a 24-month RCT with both clinical and
radiographic primary endpoints [14, 124]. In the study, 632
MTX-naı¨ve early RA patients were randomised to receive
either twice weekly subcutaneous ETN (10 or 25mg) or
weekly escalating doses of oral MTX (7.5–20mg/week). The
patients in the group assigned to the higher ETN dose had
significantly greater areas under the curve for the numeric
index of the ACR response [ACR-N AUC] at 3, 6, 9, and
12 months than did the patients in the MTX group (𝑃 <
0.05). However, no differences in the proportion of patients
achieving ACR20 (72% versus 65%; 𝑃 = 0.16), 50, and 70
responses at 12months were found in the comparison of ETN
and MTX treated groups. The mean increase in the erosion
score was significantly lower in the 25-mg ETN group than in
theMTXgroup at both 6-month (0.30 versus 0.68;𝑃 = 0.001)
and 12-month (0.47 versus 1.03; 𝑃 = 0.002) evaluations, as
well as the mean total modified sharp score (mTSS) increases
at 6months (0.57 versus 1.06;𝑃 = 0.001), but not at 12months
(1.00 versus 1.59; 𝑃 = 0.11) [14]. At 24 months, significantly
more patients in the 25-mg ETN group than in the MTX
group achieved an ACR20 response (72% versus 59%; 𝑃 =
0.005) and the mean changes in mTSS and erosion score in
the 25-mg ETN treated patients (1.3 and 0.66 units, resp.)
were significantly lower than those in the MTX group (3.2
and 1.86 units, resp.; 𝑃 < 0.001) [124]. The safety outcomes
through the entire 2-year follow-up period were comparable
between the two treatment drugs in terms of both infectious
and noninfectious events, with the only exception of injection
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site reactions (ETN 25mg 39% versus MTX 9%; 𝑃 < 0.05),
nausea (ETN 25mg 14% versusMTX 31%;𝑃 < 0.05), alopecia
(ETN 25mg 6% versus MTX 12%; 𝑃 < 0.05), and mouth
ulcers (ETN 25mg 5% versus MTX 17%; 𝑃 < 0.05).
The AMBITION trial [125] is a 6-month RCT including
673 patients with active RA for whom previous treatment
with MTX had not failed. Study population was randomly
assigned either TCZ 8mg/kg every 4 weeks, or MTX (start-
ing at 7.5mg/weekly and titrated to 20mg/weekly within 8
weeks), with the proportion of patients achieving ACR20
response at week 24 as the primary endpoint. The intention-
to-treat analysis demonstrated that TCZ monotherapy was
better than MTX with higher ACR20 (69.9% versus 52.5%;
𝑃 < 0.001), ACR50 (44.1% versus 33.5%; 𝑃 = 0.002), and
ACR70 (28% versus 15.1%; 𝑃 < 0.001) responses. Moreover,
TCZ patients were five times more likely to achieve DAS28
remission (odds ratio versus MTX: 5.83; 95% confidence
interval [CI] 3.27 to 10.40), and approximately four times
more likely to achieve at least a moderate EULAR response
(odds ratio versus MTX: 4.24, 95% CI 2.92 to 6.14). No
significant differences between TCZ and MTX were found
in the incidence of AEs (79.9% versus 77.5%; 𝑃 = 0.484),
serious AEs (3.8% versus 2.8%, 𝑃 = 0.50), and serious
infections (1.4% versus 0.7%). Furthermore, TCZ treated
patients showed a higher incidence of reversible grade-3
neutropenia (3.1% TCZ versus 0.4% MTX) and increased
total cholesterol ≥240mg/dL (13.2% TCZ versus 0.4%MTX),
and a lower incidence of alanine aminotransferase elevations
>3x–<5x upper limit of normal (1.0%TCZversus 2.5%MTX).
In the TEMPO trial [27] 686 RA patients were ran-
domised to receive oral MTX (up to 20mg/week), ETN
(25mg twice a week), or the combination of both, with
clinical (24 weeks ACR-N AUC) and radiological (52 weeks
mTSS change from baseline) primary endpoints. The combi-
nation therapy was significantly better than ETN and MTX
monotherapies in reduction of disease activity, improvement
of functional disability, and retardation of radiographic pro-
gression.
Focusing on direct comparison between ETN and MTX
groups, no statistically significant differences emerged in
terms of 1-year clinical response (ACR20 76% versus 75%,
ACR50 48% versus 43%, and ACR70 24% versus 19%, resp.),
whereas 1-year damage worsening was significantly lower in
the ETN group compared with MTX (proportion of patient
without progression 68% versus 57%, resp.; 𝑃 = 0.02. Mean
mTSS change from baseline 0.52 versus 2.80, resp.; 𝑃 =
0.04). This finding was confirmed by 2-years follow-up data,
showing a significantly lower mean change from baseline
in mTTS in patients receiving ETN compared with those
receiving MTX (1.10 versus 3.34, resp.; 𝑃 = 0.05) [123]. The
proportion of patients reporting AEs (ETN 86% versus MTX
81%) or serious infections (ETN 4% versus MTX 4%) was
comparable between ETN and MTX groups.
As well as TEMPO trial, PREMIER study [12] was
designed by randomising 799 early MTX-naı¨ve RA patients
into 3 treatment arms (oral MTX 20mg/weekly, ADA
40mg/every other week, or the combination of both). Copri-
mary endpoints at year 1 were ACR50 improvement and
mean change from baseline in the mTTS. Similarly to what
previously reported in theTEMPO trial, combination therapy
was superior to both ADA and MTX monotherapies in all
clinical and radiographic outcomes measured, whereas the
proportion of 12- and 24-monthACR20 (54% versus 63% and
49% versus 56%, resp.), ACR50 (41% versus 46% and 37%
versus 43%, resp.), and ACR70 (26% versus 28% and 28%
versus 28%, resp.) responses were comparable between ADA
and MTX groups. Otherwise, damage progression at both 1-
and 2-year evaluationswas significantly lower inADA treated
patients directly compared with MTX treated ones (mean
change from baseline in mTTS 3.0 versus 5.7 and 5.5 versus
10.4, resp.; 𝑃 < 0.001). The incidence of serious AEs and
serious infections (21.1 versus 15.9 and 0.7 versus 1.6 per 100
patient years, resp.) was similar in bothmonotherapy groups.
5.3. Biological DMARDs versus Biological DMARDs. The
head-to-head comparison between 2 different biological
agents is available only in 2 RCTs, the ADACTA trial (com-
paring TCZ and ADA monotherapies) and the AMPLE trial
(comparing ABT and ADA, both on top of MTX) (Table 2).
The ATTEST study [20] and the ORAL STANDARD study
[126] were excluded since they were designed with the
statistical power for comparing biologic drugs against a
common placebo group only but not against each other.
ADACTA is the first head-to-head superiority RCT com-
paring TCZ (8mg/kg every 4 weeks) and ADA (40mg every
other week) monotherapy in a study population of MTX-
insufficient responder RA patients (𝑛 = 335) [127]. TCZ
monotherapywas superior to ADAmonotherapy at 6months
according to all main efficacy endpoints: EULAR remission
(39.9%versus 10.5%;𝑃 < 0.0001), EULAR lowdisease activity
(51.5% versus 19.8%; 𝑃 < 0.0001), ACR20 (65% versus 49.4%;
𝑃 = 0.003), ACR50 (47.2% versus 27.8%; 𝑃 = 0.0002), ACR70
(32.5% versus 17.9%; 𝑃 = 0.002), and CDAI remission (17.2%
versus 9.3%; 𝑃 = 0.03). The kinetics of clinical response in
the two groups were comparable through the entire follow-
up period. The adverse event profiles of TCZ and ADA were
similar and consistent with previous findings. In particular,
no significant differences were found between the 2 treatment
groups in the 6-month rate of overall (82% versus 83%)
and serious (12% versus 10%) AEs, and overall (70% versus
65%) and serious (4% versus 4%) infections, as well as in
the frequency of transaminase elevation ≤2.5x upper limit of
normal (32% versus 25%). Otherwise, some differences in the
effect of the two drugs on the neutrophil count have been
registered, with a proportion of patients experiencing grade-2
neutropenia (<1500–1000x mm3) with TCZ higher than with
ADA (13% versus 4%), even if cases of severe neutropenia
were very rare in both the treatment groups.
The AMPLE trial provided a noninferiority comparison
of subcutaneous ABT and ADA, both administrated in
combination with MTX, in a study population of 646 RA
patients through a 2-year follow-up period [128, 129]. The
clinical efficacy of ABT and ADA is comparable according to
1 and 2 years ACR20 (64.8% versus 63.8% and 60.1% versus
59.7%, resp.), ACR50 (46.2% versus 46% and 46.6% versus
44.7%, resp.), andACR70 improvements (29.2% versus 26.2%
and 31.1% versus 29.3, resp.), with similar kinetics of response
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throughout the entire 2-year follow-up period. Similarly,
no significant differences emerged in the comparison of
radiographic progression in ABT and ADA treated patients,
with more than 80% nonprogressor patients in both the
groups. Finally, 2-year safety outcomes are balanced, but
with some notable differences in the incidence of AEs (10.1%
versus 9.1%), serious AEs (1.6% versus 4.9%), and serious
infections (0 versus 2.7%) and injection site reactions (4.1%
versus 10.4%), all in favour of ABT compared with ADA.
6. Conclusions
The arsenal of therapeutic options for RA is vast, but
knowledge on the optimal use of different drugs in individual
patients in typical day-to-day practice remains poor. Over a
period of more than 25 years, only 20 head-to-head RCTs
comparing two different DMARDs have been performed,
providing some preliminary but encouraging suggestion on
how to deal with the complexity of the available therapeutic
armamentarium. Key messages emerging from direct com-
parisons are as follows.
(i) MTX overall risk/benefit ratio is the most favourable
comparedwith other syntheticDMARDs, confirming
its use as first line therapy and LEF or SSZ as
an alternative treatment in newly diagnosed RA, as
suggested by international guidelines [53].
(ii) TCZ is the only biologic DMARD with a demon-
strated clinical superiority compared to MTX. ETN
and ADA have been shown to be able only to slow
damage progression better thanMTX, without signif-
icant differences in clinical response.
(iii) TCZ monotherapy is superior to ADA monotherapy,
with a similar safety profile.
(iv) Clinical efficacy, damage progression, and kinetics of
response of sc ABT and ADA are comparable. Safety
profiles are quite similar, slightly in favour of ABT.
It is hoped that future years will witness a radical shift
in the way medical research is conceived and performed in
RA. More direct comparisons and innovative trial designs
will help achieving the final goal of treating the right patient
at the right time with the right drug.
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